The U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab) on November 7, 2023. This approval, identified as BLA 125514 S-148, signifies an update to the drug's label based on new efficacy data reviewed by the agency.
Background
Pembrolizumab (Keytruda) is an immunotherapy drug. This supplemental approval, specifically categorized for 'Efficacy,' indicates that the FDA has reviewed and accepted new data demonstrating the drug's effectiveness for an expanded use. Such approvals typically broaden the scope of patients who can benefit from the treatment or add new indications to the drug's label.
What this means
This supplemental efficacy approval for Keytruda signifies an expansion of its approved therapeutic applications. For healthcare providers, this means that pembrolizumab is now indicated for an additional use or patient population, supported by new clinical evidence. Researchers will find the detailed efficacy data in the official FDA documents, which will inform future studies and clinical guidelines. Patient advocates can use this information to understand the evolving treatment landscape and discuss new options with their care teams. The specific details of the new indication or patient population are contained within the full approval documentation from the FDA.
Source
The information regarding this supplemental application approval was sourced from the U.S. Food and Drug Administration (FDA) on November 7, 2023. The details are available on the accessdata.fda.gov website, under BLA 125514 S-148.